Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.

Om avsnittet

Fler avsnitt

Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

Dose Makes the Cure: Venetoclax in Ph- ALL

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow

Predictive Markers of Glofitamab Resistance in R/R B-NHL

Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

FLT3-ITD microclones in AML and Results from the RESET-PV trial